US Patent

US9993461 — Method for treating disorders associated with glomerular function

Method of Use · Assigned to Ligand Pharmaceuticals Inc · Expires 2030-03-29 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses methods of administering a biphenyl sulfonamide compound as a dual angiotensin and endothelin receptor antagonist for treating diseases.

USPTO Abstract

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Drugs covered by this patent

sparsentan (SPARSENTAN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3269`	—	sparsentan
`U-3269`	—	sparsentan

Patent Metadata

Patent number: US9993461
Jurisdiction: US
Classification: Method of Use
Expires: 2030-03-29
Drug substance claim: No
Drug product claim: No
Assignee: Ligand Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.